Show simple item record

dc.contributor.authorRand, K.
dc.contributor.authorRamos-Goñi, J. M.
dc.contributor.authorAkmaz, B.
dc.contributor.authorSolé-Feu, L.
dc.contributor.authorArmario Hita, José Carlos 
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2024-06-26T11:29:16Z
dc.date.available2024-06-26T11:29:16Z
dc.date.issued2024-03-05
dc.identifier.issn2190-9172
dc.identifier.issn2193-8210
dc.identifier.urihttp://hdl.handle.net/10498/32774
dc.description.abstractLetteres_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherAdises_ES
dc.rightsAttribution-NonCommercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceDermatology and Therapyes_ES
dc.titleResponse to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”es_ES
dc.typeotheres_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doihttps://doi.org/10.1007/s13555-024-01106-2
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial 4.0 Internacional